FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030378344> ?p ?o ?g. }

• W3030378344 abstract "e15227 Background: Infliximab is used to treat steroid-refractory immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICI). Current dogma holds that infliximab is contraindicated in immune hepatitis; steroid refractory disease should be managed with mycophenolate mofetil (MMF). This is based on anecdotal reports of infliximab-induced hepatotoxicity in patients with rheumatologic diseases who received multiple infusions of the drug. In this series of 56 consecutive cases of infliximab-treated patients, we assessed the efficacy of infliximab in resolving specific steroid-refractory irAEs and evaluated the risk of hepatotoxicity from this drug. Methods: We reviewed consecutive patients treated with infliximab for steroid-refractory irAE at a tertiary cancer center between January 2010 and February 2019. To judge hepatotoxicity, we used the Wilcoxon signed rank test to compare the mean value of ALT, AST and total bilirubin (BT) between 0-4 weeks before and after infliximab therapy. We compared factors associated with infliximab efficacy by logistic regression. A p value < 0.05 was considered statistically significant. Results: Mean age was 61.9 years. The majority had a diagnosis of melanoma (62%); 45% had a combination of two ICI before toxicity onset, of whom 73% received an anti-PD1 and an anti-CTLA-4. Colitis was the most common toxicity (66%), followed by pneumonitis (11%). Infliximab was used to treat immune related hepatitis (ir-hepatitis) in 1 patient (2%). Median number of infliximab doses was 1 (1-3), with resolution of toxicity in 76% of patients. Colitis was likely to resolve with infliximab in comparison to other irAE [OR 0.2(95% CI 0.05-0.73)]. Univariate logistic regression did not demonstrate statistical difference in toxicity outcome when ICI were given either as monotherapy (p = 0.3) or combination (p = 0.97). Mean BT, ALT and AST levels before and after infliximab were not statistically different (see table), with no evidence of infliximab-induced hepatotoxicity. The patient treated for ir-hepatitis had a complete recovery, with no further hepatotoxicity. Conclusions: Infliximab was effective in treating irAE and was not associated with hepatotoxicity in this dose-limited setting. Infliximab may be an alternative to MMF in steroid-refractory ir-hepatitis and should be tested prospectively in a randomized trial. [Table: see text]" @default.
• W3030378344 created "2020-06-05" @default.
• W3030378344 creator A5008158683 @default.
• W3030378344 creator A5009921149 @default.
• W3030378344 creator A5033270846 @default.
• W3030378344 creator A5065240674 @default.
• W3030378344 creator A5066771790 @default.
• W3030378344 creator A5070244587 @default.
• W3030378344 creator A5075690270 @default.
• W3030378344 creator A5088186975 @default.
• W3030378344 creator A5091333362 @default.
• W3030378344 date "2020-05-20" @default.
• W3030378344 modified "2023-10-16" @default.
• W3030378344 title "Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting." @default.
• W3030378344 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e15227" @default.
• W3030378344 hasPublicationYear "2020" @default.
• W3030378344 type Work @default.
• W3030378344 sameAs 3030378344 @default.
• W3030378344 citedByCount "0" @default.
• W3030378344 crossrefType "journal-article" @default.
• W3030378344 hasAuthorship W3030378344A5008158683 @default.
• W3030378344 hasAuthorship W3030378344A5009921149 @default.
• W3030378344 hasAuthorship W3030378344A5033270846 @default.
• W3030378344 hasAuthorship W3030378344A5065240674 @default.
• W3030378344 hasAuthorship W3030378344A5066771790 @default.
• W3030378344 hasAuthorship W3030378344A5070244587 @default.
• W3030378344 hasAuthorship W3030378344A5075690270 @default.
• W3030378344 hasAuthorship W3030378344A5088186975 @default.
• W3030378344 hasAuthorship W3030378344A5091333362 @default.
• W3030378344 hasConcept C126322002 @default.
• W3030378344 hasConcept C17991360 @default.
• W3030378344 hasConcept C197934379 @default.
• W3030378344 hasConcept C2777138892 @default.
• W3030378344 hasConcept C71924100 @default.
• W3030378344 hasConcept C90924648 @default.
• W3030378344 hasConceptScore W3030378344C126322002 @default.
• W3030378344 hasConceptScore W3030378344C17991360 @default.
• W3030378344 hasConceptScore W3030378344C197934379 @default.
• W3030378344 hasConceptScore W3030378344C2777138892 @default.
• W3030378344 hasConceptScore W3030378344C71924100 @default.
• W3030378344 hasConceptScore W3030378344C90924648 @default.
• W3030378344 hasLocation W30303783441 @default.
• W3030378344 hasOpenAccess W3030378344 @default.
• W3030378344 hasPrimaryLocation W30303783441 @default.
• W3030378344 hasRelatedWork W10386318 @default.
• W3030378344 hasRelatedWork W10433427 @default.
• W3030378344 hasRelatedWork W1320415 @default.
• W3030378344 hasRelatedWork W1618377 @default.
• W3030378344 hasRelatedWork W16896924 @default.
• W3030378344 hasRelatedWork W17437393 @default.
• W3030378344 hasRelatedWork W18979795 @default.
• W3030378344 hasRelatedWork W2337926 @default.
• W3030378344 hasRelatedWork W3657330 @default.
• W3030378344 hasRelatedWork W17830138 @default.
• W3030378344 isParatext "false" @default.
• W3030378344 isRetracted "false" @default.
• W3030378344 magId "3030378344" @default.
• W3030378344 workType "article" @default.